Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice

Peptides

Volumn 28, Issue 11, 2007, Pages 2192-2198

  Irwin, N ^a   Hunter, K ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Glucose homeostasis; Glucose dependent insulinotropic polypeptide (GIP); High fat feeding; Obesity; Peptide YY (PYY)

Indexed keywords

CORTICOSTERONE; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE[3 PROLINE]; GLUCAGON; GLUCOSE; HORMONE RECEPTOR; INSULIN; PEPTIDE YY; PEPTIDE YY [3-36]; PEPTIDE YY [3-36] RECEPTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; MALE; METABOLIC REGULATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; CORTICOSTERONE; DIETARY FATS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOSE TOLERANCE TEST; INSULIN; MALE; MICE; OBESITY; PEPTIDE YY; RECEPTORS, GASTROINTESTINAL HORMONE;

MUS;

EID: 35349009012     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.08.008     Document Type: Article

References (26)

1. Anini Y., Fu-Cheng X., Cuber J.C., Kervran A., Chariot J., and Roz C. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch 438 (1999) 299-306
2. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
3. Boggiano M.M., Chandler P.C., Oswald K.D., Rodgers R.J., Blundell J.E., Ishii Y., et al. PYY3-36 as an anti-obesity drug target. Obes Rev 6 (2005) 307-322
4. Burington R.S. Handbook of mathematical tables and formulae (1973), McGraw-Hill, New York
5. Challis B.G., Pinnock S.B., Coll A.P., Carter R.N., Dickson S.L., and O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311 (2003) 915-919
6. Chelikani P.K., Haver A.C., and Reidelberger R.D. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 293 (2007) R39-R46
7. Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 109 (2001) S288-S303
8. Ding K.H., Zhong Q., Xie D., Chen H.X., Della-Fera M.A., Bollag R.J., et al. Effects of glucose-dependent insulinotropic peptide on behavior. Peptides 27 (2006) 2750-2755
9. Donckier J.E. Endocrine diseases and diabetes. In: Pickup J.C., and Williams G. (Eds). Textbook of diabetes. 3rd ed. (2003), Blackwell Science Limited, Oxford 27.1-27.25
10. Drucker D.J. The role of gut hormones in glucose homeostasis. J Clin Invest 117 (2007) 24-32
11. Flatt P.R., and Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20 (1981) 573-577
12. Gault V.A., O'Harte F.P., Harriott P., and Flatt P.R. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290 (2002) 1420-1426
13. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54 (2005) 2436-2446
14. Gault V.A., McClean P.L., Cassidy R.S., Irwin N., and Flatt P.R. Chemical GIP receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high fat and cafeteria diets. Diabetologia 50 (2007) 1752-1762
15. Grandt D., Schimiczek M., Beglinger C., Layer P., Goebell H., Eysselein V.E., et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51 (1994) 151-159
16. Hansotia T., Maida A., Flock G., Yamada Y., Tsukiyama K., Seino Y., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117 (2007) 143-152
17. 3)GIP, prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob ice. Diabetologia 50 (2007) 1532-1540
18. Meier J.J., Gallwitz B., Siepmann N., Holst J.J., Deacon C.F., Schmidt W.E., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46 (2003) 798-801
19. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., and Zhou H. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8 (2002) 738-742
20. Neary N.M., Small C.J., and Bloom S.R. Gut and mind. Gut 52 (2003) 918-921
21. Pederson R.A., and Brown J.C. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99 (1976) 780-785
22. Stevens J.F. Determination of glucose by an automatic analyzer. Clin Chem Acta 32 (1971) 199-201
23. Szecowka J., Tatemoto K., Rajamaki G., and Efendic S. Effects of PYY and PP on endocrine pancreas. Acta Physiol Scand 119 (1983) 123-126
24. Tatemoto K., and Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285 (1980) 417-418
25. Woods S.C., West D.B., Stein L.J., McKay L.D., Lotter E.C., Porte S.G., et al. Peptides and the control of meal size. Diabetologia 20 (1991) S305-S313
26. Yamada Y., Miyawaki K., Tsukiyama K., Harada N., Yamada C., and Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 55 (2006) S86-S91